MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults

OBJECTIVE: Growth hormone (GH) replacement therapy currently requires daily injections, which may cause distress and low compliance. C-terminal peptide (CTP)-modified growth hormone (MOD-4023) is being developed as a once-weekly dosing regimen in patients with GH deficiency (GHD). This study’s objec...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Eur J Endocrinol
मुख्य लेखकों: Strasburger, Christian J, Vanuga, Peter, Payer, Juraj, Pfeifer, Marija, Popovic, Vera, Bajnok, László, Góth, Miklós, Olšovská, Veˇra, Trejbalová, L‘udmila, Vadasz, Janos, Fima, Eyal, Koren, Ronit, Amitzi, Leanne, Bidlingmaier, Martin, Hershkovitz, Oren, Hart, Gili, Biller, Beverly M K
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Bioscientifica Ltd 2016
विषय:
Clinical Study
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5292974/
https://ncbi.nlm.nih.gov/pubmed/27932411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-16-0748
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन